EUVIMEDEUVIMED entdecken
Open Access

Examination of the PET in vivo generator 134Ce as a theranostic match for 225Ac

David Bauer iD, Roberto De Gregorio iD, Edwin C Pratt iD, Abram Bell iD, Alexa Michel iD, Jason S Lewis iD

European Journal of Nuclear Medicine and Molecular Imaging · 2024

DOI: 10.1007/s00259-024-06811-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2024. Verfasst von David Bauer und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and the Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. b…. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Actinium, Cerium. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The radionuclide pair cerium-134/lanthanum-134 (134Ce/134La) was recently proposed as a suitable diagnostic counterpart for the therapeutic alpha-emitter actinium-225 (225Ac). The unique properties of 134Ce offer perspectives for developing innovative in vivo investigations that are not possible with 225Ac. In this work, 225Ac- and 134Ce-labelled tracers were directly compared using internalizing and slow-internalizing cancer models to evaluate their in vivo comparability, progeny meandering, and potential as a matched theranostic pair for clinical translation. Despite being an excellent chemical match, 134Ce/134La has limitations to the setting of quantitative positron emission tomography imaging. METHODS: The precursor PSMA-617 and a macropa-based tetrazine-conjugate (mcp-PEG8-Tz) were radiolabelled with 225Ac or 134Ce and compared in vitro and in vivo using standard (radio)chemical methods. Employing biodistribution studies and positron emission tomography (PET) imaging in athymic nude mice, the radiolabelled PSMA-617 tracers were evaluated in a PC3/PIP (PC3 engineered to express a high level of prostate-specific membrane antigen) prostate cancer mouse model. The 225Ac and 134Ce-labelled mcp-PEG8-Tz were investigated in a BxPC-3 pancreatic tumour model harnessing the pretargeting strategy based on a trans-cyclooctene-modified 5B1 monoclonal antibody. RESULTS: In vitro and in vivo studies with both 225Ac and 134Ce-labelled tracers led to comparable results, confirming the matching pharmacokinetics of this theranostic pair. However, PET imaging of the 134Ce-labelled precursors indicated that quantification is highly dependent on tracer internalization due to the redistribution of 134Ce's PET-compatible daughter 134La. Consequently, radiotracers based on internalizing vectors like PSMA-617 are suited for this theranostic pair, while slow-internalizing 225Ac-labelled tracers are not quantitatively represented by 134Ce PET imaging. CONCLUSION: When employing slow-internalizing vectors, 134Ce might not be an ideal match for 225Ac due to the underestimation of tumour uptake caused by the in vivo redistribution of 134La. However, this same characteristic makes it possible to estimate the redistribution of 225Ac's progeny noninvasively. In future studies, this unique PET in vivo generator will further be harnessed to study tracer internalization, trafficking of receptors, and the progression of the tumour microenvironment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron-Emission TomographyActiniumCeriumAnimalsMiceHumansTissue DistributionMaleRadiopharmaceuticalsTheranostic NanomedicineCell Line, TumorDipeptidesHeterocyclic Compounds, 1-RingProstate-Specific Antigen

Stichwörter der Autor:innen

Actinium-225Cerium-134PET imagingPretargetingProgeny releaseTargeted alpha therapy

Substanzen

ActiniumActinium-225CeriumRadiopharmaceuticalsPSMA-617DipeptidesHeterocyclic Compounds, 1-RingProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Radiology and the Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. bauerd1@mskcc.org.
  • Department of Radiology and the Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
  • Brigham Young University-Idaho, Rexburg, ID, 83440, USA.
  • Department of Radiology and the Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. lewisj2@mskcc.org.
  • Departments of Radiology and Pharmacology, Weill Cornell Medical College, New York, NY, 10065, USA. lewisj2@mskcc.org.

ORCID-Profile: David Bauer, Roberto De Gregorio, Edwin C Pratt, Abram Bell, Alexa Michel, Jason S Lewis

Förderung

  • NCI NIH HHS

Zitieren

APA

Bauer, D., De Gregorio, R., Pratt, E. C., Bell, A., Michel, A., & Lewis, J. S. (2024). Examination of the PET in vivo generator 134Ce as a theranostic match for 225Ac. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06811-w

Vancouver

Bauer D, De Gregorio R, Pratt EC, Bell A, Michel A, Lewis JS. Examination of the PET in vivo generator 134Ce as a theranostic match for 225Ac. European Journal of Nuclear Medicine and Molecular Imaging. 2024. doi:10.1007/s00259-024-06811-w

BibTeX
@article{Bauer2024,
  author = {Bauer, David and De Gregorio, Roberto and Pratt, Edwin C and Bell, Abram and Michel, Alexa and Lewis, Jason S},
  title = {Examination of the PET in vivo generator 134Ce as a theranostic match for 225Ac},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2024},
  doi = {10.1007/s00259-024-06811-w}
}
Kostenlos starten →